IFRX - צמיחת הכנסות שנתית ב-12 החודשים האחרונים inflarx.de

InflaRx N.V. (IFRX) is developing innovative complement inhibitors, leveraging government funding and the potential of vilobelimab. Prospects depend on government procurement of respiratory distress syndrome therapies subject to regulatory compliance. Year-over-year (TTM) revenue changes visualize business dynamics, where the value of 0.00 reflects this status. Growth is supported by an elite staff of German immunologists and a stable R&D budget.
InflaRx NV (IFRX) - פילוחי מדדים ודוחות פיננסיים

This indicator measures the relative change in revenue over the last four quarters, reflecting the actual speed of the business's market expansion. By analyzing the current sales growth rate over a rolling 12-month period year-over-year, an investor can promptly diagnose demand stagnation. The metric allows for an assessment of product commercialization efficiency in dynamic terms. For InflaRx N.V. (IFRX), this is critically important when launching new drugs. High promotion costs temporarily limit profits despite the scaling of revenues.